ICON vs Medpace
ICLR and MEDP side by side, both in engineering, accounting, research, management, and related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ICLR and MEDP compare
Medpace grew revenue faster over the last twelve months (24.7% versus 1.7% for ICON).
Medpace keeps more of each dollar of sales as profit, with a net margin of 17.7% compared with 0.51% at ICON.
Medpace scores higher on the StockData Score (15 against 4 for ICON), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ICLR | MEDP |
|---|---|---|
| Size and price | ||
| Market cap | – | $18.2B |
| Share price | $211.36 | $652.01 |
| Change, 1 year | 27.4% | 11.5% |
| Change, 5 years | −20.5% | 189% |
| Beta (5Y) | 1.24 | 1.39 |
| Employees | 40K | 6,200 |
| StockData Score | ||
| Total score | 4 | 15 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 4 (better) |
| Performance score | 2 | 6 (better) |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 38.2× |
| P/S | – | 6.5× |
| P/B | – | 41.9× |
| EV/EBITDA | – | 30.3× |
| P/FCF | – | 25.8× |
| PEG | – | 1.36 |
| FCF yield | – | 3.9% |
| Fair value | – | $430.99 |
| Margin of safety | – | −51.3% |
| Growth | ||
| Revenue growth (TTM) | 1.7% | 24.7% (better) |
| Revenue growth, 5Y average | 24.2% (better) | 22.3% |
| Net income growth (TTM) | −95.1% | 17.5% (better) |
| EPS growth (TTM) | −94.8% | 26.8% (better) |
| EPS growth, 5Y average | −14.0% | 31.8% (better) |
| Profitability | ||
| Gross margin | 23.9% | – |
| Operating margin | 3.6% | 21.0% (better) |
| Net margin | 0.51% | 17.7% (better) |
| FCF margin | 10.7% | 25.4% (better) |
| Return on equity | 0.45% | 162% (better) |
| Return on invested capital | 2.0% | 1674% (better) |
| Financial health | ||
| Debt / equity | 0.23 (better) | 0.00 |
| Net debt / EBITDA | 1.77 | – |
| Interest coverage | 1.5× | – |
| Current ratio | 0.95 (better) | 0.73 |
| Altman Z-score | – | 8.44 |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Buyback yield | – | 1.6% |
| Shareholder yield | – | 1.6% |
| Ownership | ||
| Held by institutions | 105% | 88.5% |
| Held by insiders | 0.57% | 20.1% |
| Insider net buying, 12 months | −$4.0M (better) | −$409M |
| Superinvestors holding | 4 (better) | 2 |
| Short interest, % of float | 3.7% | 7.2% |
Go deeper
- ICLR stock overview
- ICLR income statement
- ICLR valuation and score
- MEDP stock overview
- MEDP income statement
- MEDP valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.